# Percutaneous Irreversible Electroporation for Unresectable Hepatic Carcinoma in Poor Liver Function

> **NCT02352935** · NA · COMPLETED · sponsor: **Fuda Cancer Hospital, Guangzhou** · enrollment: 15 (actual)

## Conditions studied

- Hepatic Carcinoma

## Interventions

- **DEVICE:** NanoKnife LEDC System

## Key facts

- **NCT ID:** NCT02352935
- **Lead sponsor:** Fuda Cancer Hospital, Guangzhou
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-01
- **Primary completion:** 2020-12-01
- **Final completion:** 2021-01-01
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2021-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02352935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02352935, "Percutaneous Irreversible Electroporation for Unresectable Hepatic Carcinoma in Poor Liver Function". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT02352935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*